JP2011530540A - テトラヒドロビオプテリンを含有する医薬剤形 - Google Patents

テトラヒドロビオプテリンを含有する医薬剤形 Download PDF

Info

Publication number
JP2011530540A
JP2011530540A JP2011522346A JP2011522346A JP2011530540A JP 2011530540 A JP2011530540 A JP 2011530540A JP 2011522346 A JP2011522346 A JP 2011522346A JP 2011522346 A JP2011522346 A JP 2011522346A JP 2011530540 A JP2011530540 A JP 2011530540A
Authority
JP
Japan
Prior art keywords
tetrahydrobiopterin
dosage form
pharmaceutical dosage
aqueous solution
metabolic precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011522346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530540A5 (enExample
Inventor
ヴィットマン,ルドルフ
ベルンコップ−シュヌルク,アンドレアス
Original Assignee
オルファ スイス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オルファ スイス ゲーエムベーハー filed Critical オルファ スイス ゲーエムベーハー
Publication of JP2011530540A publication Critical patent/JP2011530540A/ja
Publication of JP2011530540A5 publication Critical patent/JP2011530540A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011522346A 2008-08-12 2009-08-07 テトラヒドロビオプテリンを含有する医薬剤形 Pending JP2011530540A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1254/2008 2008-08-12
AT12542008 2008-08-12
PCT/AT2009/000306 WO2010017570A2 (de) 2008-08-12 2009-08-07 Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin

Publications (2)

Publication Number Publication Date
JP2011530540A true JP2011530540A (ja) 2011-12-22
JP2011530540A5 JP2011530540A5 (enExample) 2012-06-07

Family

ID=41111155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522346A Pending JP2011530540A (ja) 2008-08-12 2009-08-07 テトラヒドロビオプテリンを含有する医薬剤形

Country Status (8)

Country Link
US (1) US20110144117A1 (enExample)
EP (1) EP2309983B1 (enExample)
JP (1) JP2011530540A (enExample)
ES (1) ES2736730T3 (enExample)
PL (1) PL2309983T3 (enExample)
RU (1) RU2011109210A (enExample)
TR (1) TR201910287T4 (enExample)
WO (1) WO2010017570A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029096A (ja) * 2013-01-10 2016-03-03 ニュートリショナル セラピューティクス インコーポレイテッド ディー/ビー/エーエヌティーアイ インコーポレイテッド 健康の維持ならびに急性および慢性障害の治療のための脂質サプリメントを含有するチュアブルウエハース
JP2017509623A (ja) * 2014-03-31 2017-04-06 ヴァソファーム ゲーエムベーハー ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP2020068734A (ja) * 2018-11-01 2020-05-07 国立大学法人東京工業大学 Sprをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物
JP2020532535A (ja) * 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107759A1 (ja) * 2004-05-11 2005-11-17 Daiichi Asubo Pharma Co., Ltd. Bh4反応性高フェニルアラニン血症治療剤
US20060211701A1 (en) * 2002-12-20 2006-09-21 Ania Muntau-Heger Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
JP2588191B2 (ja) * 1987-04-24 1997-03-05 サントリー株式会社 悪性腫瘍および重症ウイルス感染症に伴う神経症状を改善するための治療剤
EP2436379A1 (en) * 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
US20060188492A1 (en) * 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
AU2006245770A1 (en) * 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the PDE4 inhibitor roflumilast and a tetrahydrobiopterin derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211701A1 (en) * 2002-12-20 2006-09-21 Ania Muntau-Heger Use of von tetrahydrobiopterine derivatives in the treatment and nutrition of patients with amino acid metabolic disorders
WO2005107759A1 (ja) * 2004-05-11 2005-11-17 Daiichi Asubo Pharma Co., Ltd. Bh4反応性高フェニルアラニン血症治療剤
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013051901; MUNTAU, A.C. et al.: The New England Journal of Medicine Vol.347, No.26, 2002, p.2122-2132 *
JPN6013051902; VALENT, S. et al.: The International Journal of Biochemistry & Cell Biology Vol.36, 2004, p.1266-1280 *
JPN6013051903; VALENT, S. et al.: The International Journal of Biochemistry & Cell Biology Vol.38, 2006, p.1786-1793 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029096A (ja) * 2013-01-10 2016-03-03 ニュートリショナル セラピューティクス インコーポレイテッド ディー/ビー/エーエヌティーアイ インコーポレイテッド 健康の維持ならびに急性および慢性障害の治療のための脂質サプリメントを含有するチュアブルウエハース
JP2017509623A (ja) * 2014-03-31 2017-04-06 ヴァソファーム ゲーエムベーハー ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
JP2019194227A (ja) * 2014-03-31 2019-11-07 ヴァソファーム ゲーエムベーハー ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
US10493075B2 (en) 2014-03-31 2019-12-03 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
US10925877B2 (en) 2014-03-31 2021-02-23 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
US11717522B2 (en) 2014-03-31 2023-08-08 Vasopharm Gmbh Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
JP2020532535A (ja) * 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
US11752154B2 (en) 2017-09-01 2023-09-12 Ptc Therapeutics Mp, Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
US12213982B2 (en) 2017-09-01 2025-02-04 Ptc Therapeutics Mp, Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
JP2020068734A (ja) * 2018-11-01 2020-05-07 国立大学法人東京工業大学 Sprをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物
JP2023041849A (ja) * 2018-11-01 2023-03-24 宏 一瀬 Sprをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物

Also Published As

Publication number Publication date
US20110144117A1 (en) 2011-06-16
WO2010017570A2 (de) 2010-02-18
EP2309983B1 (de) 2019-04-24
RU2011109210A (ru) 2012-09-20
PL2309983T3 (pl) 2019-09-30
ES2736730T3 (es) 2020-01-07
EP2309983A2 (de) 2011-04-20
TR201910287T4 (tr) 2019-07-22
WO2010017570A3 (de) 2010-08-05

Similar Documents

Publication Publication Date Title
KR101721198B1 (ko) 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
RU2661033C9 (ru) Стабильные композиции тетрагидробиоптерина
JP2011530540A (ja) テトラヒドロビオプテリンを含有する医薬剤形
US20200323776A1 (en) Diclofenac formulations and methods of use
JP2022107687A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
KR20240105361A (ko) L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법
US11957685B2 (en) Pharmaceutical compositions of tofacitinib for oral administration
EP1964566A1 (en) Preparation with improved bioabsorbability of sapropterin hydrochloride
US20090082305A1 (en) Method of improving storage stability of substance
US20250345336A1 (en) Allopurinol oral suspension
WO2021100728A1 (ja) 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤
TW201414476A (zh) 經改善溶出性及/或吸收性之經口投予用醫藥組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401